ORIC Pharmaceuticals (ORIC) to Release Earnings on Monday

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.01. On average, analysts expect ORIC Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ORIC Pharmaceuticals Trading Up 1.8 %

NASDAQ ORIC traded up $0.10 during trading on Friday, hitting $5.67. 482,668 shares of the company's stock were exchanged, compared to its average volume of 637,294. The company has a market cap of $403.05 million, a PE ratio of -3.12 and a beta of 1.38. ORIC Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The stock's 50 day moving average price is $6.17 and its two-hundred day moving average price is $8.20.

Analyst Ratings Changes

A number of brokerages have weighed in on ORIC. Cantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Wedbush reissued an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $18.86.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.